Literature DB >> 15901925

Sulforhodamine B assay and chemosensitivity.

Wieland Voigt1.   

Abstract

The sulforhodamine B (SRB) assay was developed by Skehan and colleagues to measure drug-induced cytotoxicity and cell proliferation for large-scale drug-screening applications. Its principle is based on the ability of the protein dye sulforhodamine B to bind electrostatically and pH dependent on protein basic amino acid residues of trichloroacetic acid-fixed cells. Under mild acidic conditions it binds to and under mild basic conditions it can be extracted from cells and solubilized for measurement. Results of the SRB assay were linear with cell number and cellular protein measured at cellular densities ranging from 1 to 200% of confluence. Its sensitivity is comparable with that of several fluorescence assays and superior to that of Lowry or Bradford. The signal-to-noise ratio is favorable and the resolution is 1000-2000 cells/well. It performed similarly compared to other cytotoxicity assays such as MTT or clonogenic assay. The SRB assay possesses a colorimetric end point and is nondestructive and indefinitely stable. These practical advances make the SRB assay an appropriate and sensitive assay to measure drug-induced cytotoxicity even at large-scale application.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15901925     DOI: 10.1385/1-59259-869-2:039

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  46 in total

1.  The slow cell death response when screening chemotherapeutic agents.

Authors:  Joseph Blois; Adam Smith; Lee Josephson
Journal:  Cancer Chemother Pharmacol       Date:  2010-12-31       Impact factor: 3.333

2.  Rescuing iron-overloaded macrophages by conservative relocation of the accumulated metal.

Authors:  Yang-Sung Sohn; Anna-Maria Mitterstiller; William Breuer; Guenter Weiss; Z Ioav Cabantchik
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

3.  ARHI (DIRAS3) induces autophagy in ovarian cancer cells by downregulating the epidermal growth factor receptor, inhibiting PI3K and Ras/MAP signaling and activating the FOXo3a-mediated induction of Rab7.

Authors:  Z Lu; H Yang; M N Sutton; M Yang; C H Clarke; W S-L Liao; R C Bast
Journal:  Cell Death Differ       Date:  2014-04-25       Impact factor: 15.828

4.  The p53 Target Gene SIVA Enables Non-Small Cell Lung Cancer Development.

Authors:  Jeanine L Van Nostrand; Alice Brisac; Stephano S Mello; Suzanne B R Jacobs; Richard Luong; Laura D Attardi
Journal:  Cancer Discov       Date:  2015-03-26       Impact factor: 39.397

5.  Multiwell stiffness assay for the study of cell responsiveness to cytotoxic drugs.

Authors:  Silviya Zustiak; Ralph Nossal; Dan L Sackett
Journal:  Biotechnol Bioeng       Date:  2013-09-06       Impact factor: 4.530

6.  Combined Scaffold Evaluation and Systems-Level Transcriptome-Based Analysis for Accelerated Lead Optimization Reveals Ribosomal Targeting Spirooxindole Cyclopropanes.

Authors:  Kevin X Rodriguez; Erin N Howe; Emily P Bacher; Miranda Burnette; Jennifer L Meloche; Jayda Meisel; Patricia Schnepp; Xuejuan Tan; Mayland Chang; Jeremiah Zartman; Siyuan Zhang; Brandon L Ashfeld
Journal:  ChemMedChem       Date:  2019-07-01       Impact factor: 3.466

7.  Guanylate-Binding Protein-1 protects ovarian cancer cell lines but not breast cancer cell lines from killing by paclitaxel.

Authors:  Aaron R Tipton; Geoffrey O Nyabuto; Jill A Trendel; Travis M Mazur; John P Wilson; Suzan Wadi; Jacob S Justinger; Garret L Moore; Peter T Nguyen; Deborah J Vestal
Journal:  Biochem Biophys Res Commun       Date:  2016-08-31       Impact factor: 3.575

8.  Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents.

Authors:  Laxman Devkota; Chen-Ming Lin; Tracy E Strecker; Yifan Wang; Justin K Tidmore; Zhi Chen; Rajsekhar Guddneppanavar; Christopher J Jelinek; Ramona Lopez; Li Liu; Ernest Hamel; Ralph P Mason; David J Chaplin; Mary Lynn Trawick; Kevin G Pinney
Journal:  Bioorg Med Chem       Date:  2016-01-06       Impact factor: 3.641

9.  Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia.

Authors:  Blake A Winn; Laxman Devkota; Bunnarack Kuch; Matthew T MacDonough; Tracy E Strecker; Yifan Wang; Zhe Shi; Jeni L Gerberich; Deboprosad Mondal; Alejandro J Ramirez; Ernest Hamel; David J Chaplin; Peter Davis; Ralph P Mason; Mary Lynn Trawick; Kevin G Pinney
Journal:  J Nat Prod       Date:  2020-03-20       Impact factor: 4.050

10.  Lack of functional alpha-lactalbumin prevents involution in Cape fur seals and identifies the protein as an apoptotic milk factor in mammary gland involution.

Authors:  Julie A Sharp; Christophe Lefèvre; Kevin R Nicholas
Journal:  BMC Biol       Date:  2008-11-06       Impact factor: 7.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.